Kutschera, Maximilian
Novacek, Gottfried
Reinisch, Walter
Högenauer, Christoph
Petritsch, Wolfgang
Haas, Thomas
Moschen, Alexander
Dejaco, Clemens http://orcid.org/0000-0002-4236-6700
Funding for this research was provided by:
Pfizer
Medical University of Vienna
Article History
Received: 25 September 2022
Accepted: 17 October 2022
First Online: 1 December 2022
Conflict of interest
: G. Novacek has received consulting fees from AbbVie, MSD, Takeda, Janssen, Sandoz, Pfizer, Astro Pharma, Falk Pharma, Ferring, Gilead, Galapagos and Vifor. W. Reinisch received fees from Abbvie, Algernon, Amgen, AM Pharma, AMT, AOP Orphan, Arena Pharmaceuticals, Astellas, Astra Zeneca, Avaxia, Roland Berger GmBH, Bioclinica, Biogen IDEC, Boehringer-Ingelheim, Bristol-Myers Squibb, Calyx, Cellerix, Chemocentryx, Celgene, Centocor, Celltrion, Covance, Danone Austria, DSM, Elan, Eli Lilly, Ernest & Young, Falk Pharma GmbH, Ferring, Galapagos, Gatehouse Bio Inc., Genentech, Gilead, Grünenthal, ICON, Index Pharma, Inova, Intrinsic Imaging, Janssen, Johnson & Johnson, Kyowa Hakko Kirin Pharma, Landos Biopharma, Lipid Therapeutics, LivaNova, Mallinckrodt, Medahead, MedImmune, Millenium, Mitsubishi Tanabe Pharma Corporation, MSD, Nash Pharmaceuticals, Nestle, Nippon Kayaku, Novartis, Ocera, OMass, Otsuka, Parexel, PDL, Periconsulting, Pharmacosmos, Philip Morris Institute, Pfizer, Procter & Gamble, Prometheus, Protagonist, Provention, Quell Therapeutics, Robarts Clinical Trial, Sandoz, Schering-Plough, Second Genome, Seres Therapeutics, Setpointmedical, Sigmoid, Sublimity, Takeda, Teva Pharma, Therakos, Theravance, Tigenix, UCB, Vifor, Zealand, Zyngenia, and 4SC. C. Högenauer is speaker for Takeda, Janssen, Pfizer, Abbvie, MSD, Falk, Sandoz, Ferring, Astro, Galapagos and consultant for Takeda, Janssen, Pfizer, Abbvie, MSD, Galapagos, Ferring. W. Petritsch has received consulting fees and speaker fees from AbbVie, Dr. Falk Pharma, MSD, Takeda. T. Haas has served as a speaker/consultant/advisory board member for Abbvie, MSD, Takeda, Janssen, Atro Pharma and Sandoz. A. Moschen reports grants and personal fees from MSD, research support and personal fees from AbbVie, research support and personal fees from Takeda, grant support and personal fees from Pfizer, grants and personal fees from Amgen, personal fees from Ferring, Janssen, Dr Falk, Novartis (Sandoz), Nestlé, Gebro Pharma, Norgine, Vifor, Astro Pharma outside the submitted work. C. Dejaco has served as a speaker/consultant/advisory board member for Abbvie, Astro Pharma, Bayer, Falk Pharma GmbH, Janssen, MSD, Pfizer, Takeda and Vifor. M. Kutschera declares that he has no competing interests.